1537 South Novato Blvd, #5
Novato, CA 94947
United States
657 208 0890
https://www.mosaicie.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 3
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Steven W. King | Chairman of the Board, President & CEO | 267,84k | N/D | 1964 |
Mr. Paul J. Lytle CPA | Executive VP, CFO, Secretary & Director | 295,53k | N/D | 1968 |
Mr. Joseph S. Shan M.P.H. | Head of Clinical Operations | N/D | N/D | 1973 |
Dr. Marvin R. Garovoy M.D. | Head of Medical Immuno-Oncology | N/D | N/D | 1944 |
Cyril Empig Ph.D. | Head of Vaccine Development | N/D | N/D | N/D |
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate is MIE-101 which is based on cowpea mosaic virus which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.
L'ISS Governance QualityScore di Mosaic ImmunoEngineering, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.